2017 will mark the 5th anniversary of the passing of Andrew Lansley’s Health and Social Care Act. Its Royal Assent signalled a period of great change and new ambitions. Some things didn’t change however. There was no new money, and demand continued to grow.
Having spent six years developing processes for evaluating treatments for rare diseases, leading the Highly Specialised Technologies (HST) programme at NICE and developing Health Technology Assessments with the Advisory Group for National Specialised Commissioning, I am all too familiar with the challenges in assessing high-cost, low-volume treatments.
The fallout from last Thursday's momentous result is ongoing. The predictions of a decision to leave the EU stretch from a return to recession, to a global crisis akin to a nuclear Armageddon. The rhetoric will surely moderate, but resolution could be some time away, as both principle English parties look to new leadership and realignment.
2016 will be "the year of merger mania," reported the future gazing PwC Health Research Institute even before the dust had settled in 2015, joining an increasing chorus of market analysts as they pour over the future prospects for the pharma sector. But with a global market of US $300 billion a year there is a lot to play for.
The Government will hold a referendum on Britain’s membership of the EU on 23 June. With the National Centre for Social Research’s latest poll of polls showing a narrow lead for the Remain campaign, a Brexit is still very much a possibility. Health in the Brexit spotlight. In recent weeks, the confrontation has spread to another politically charged area: the NHS.
Doctor strikes, funding crises, lengthening waiting times: so much recent NHS focus has been on what it can’t do. So it’s refreshing to spend time seeing what it can do. That was the main thrust of UK e-Health Week - an event held last week at Olympia in London. It’s easy to glibly say ‘the NHS needs to be more digital’. But what does this digital future look like?
At times in recent months the number of competing claims to achieving a long term solution to evaluating new specialty medicines has resembled the race to the South Pole as NICE, NHS England and DH have all had review processes underway. What emerged yesterday with the publication of the interim findings of the Accelerated Access review is a consensus around conditionality.
As Parliament returns from the summer recess, the real politics and policy making of this new parliamentary term gets underway. With NHS England and NICE poised to announce a major consultation on how the health system values new medicines and a brutal delisting of established medicines from the cancer drugs fund , the pattern for the next five years is set.
NHS Procurement Champion and Labour Peer Lord Carter of Coles has published an interim report setting out findings from his review of NHS procurement and standards. Announced in 2014, the review’s goal is to help the NHS identify £22bn of efficiency savings required in the next five years. Carter’s team analysed cost data across four broad categories of expenditure.
After a lengthy delay, Jeremy Hunt has finally announced that the Innovative Medicines and Med Tech review will be led by Sir Hugh Taylor, chair of Guys and St Thomas’ NHS Trust, and supported by an expert advisory group to be led by Sir John Bell, Regius Professor of Medicine at Oxford University. Sir Hugh […]
Measurement and evaluation